Article
Medicine, General & Internal
Sofia Tejada, Miia Jansson, Candela Sole-Lleonart, Jordi Rello
Summary: Neuraminidase inhibitors (NAIs) therapy significantly reduced the time to clinical resolution, total influenza-related complications, acute otitis media and need for antibiotic treatment. While reductions in mortality, pneumonia, asthma exacerbations, and hospitalization rates only demonstrated a trend benefit with NAIs treatment. The most significant adverse event associated with NAIs was an increase in nausea and vomiting.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Infectious Diseases
Deepali Kumar, Michael G. Ison, Jean-Paul Mira, Tobias Welte, Jick Hwan Ha, David S. Hui, Nanshan Zhong, Takefumi Saito, Laurie Katugampola, Neil Collinson, Sarah Williams, Steffen Wildum, Andrew Ackrill, Barry Clinch, Nelson Lee
Summary: This study tested the combination of baloxavir with NAIs in hospitalized patients with severe influenza but found no superior clinical outcomes compared to NAIs alone. The combination was well tolerated, suggesting that combination antivirals may not be routinely indicated in clinical practice for this patient population.
LANCET INFECTIOUS DISEASES
(2022)
Review
Medicine, General & Internal
Jen-Wei Liu, Shen-Hua Lin, Lin-Chien Wang, Hsiao-Yean Chiu, Jen-Ai Lee
Summary: This study compared the efficacy and safety of neuraminidase inhibitors and the endonuclease inhibitor for the treatment of seasonal influenza among healthy adults and children. The results showed that zanamivir was associated with the shortest time to alleviation of influenza symptoms, while baloxavir was associated with reduced rate of influenza-related complications.
Article
Pharmacology & Pharmacy
Sofia Tejada, Alexandre M. Tejo, Yolanda Pena-Lopez, Carlos G. Forero, Xavier Corbella, Jordi Rello
Summary: The study found that baloxavir and neuraminidase inhibitors (NAIs) have a significant reduction effect on complications of uncomplicated influenza, especially in reducing antibiotic prescriptions. Single-dose baloxavir is non-inferior to NAIs in terms of safety and efficacy.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Article
Environmental Sciences
Magdalena Swierczynska, Dagmara M. Mirowska-Guzel, Edyta Pindelska
Summary: This article presents the possibilities of using all available antiviral drugs specific for influenza A and B, and compares the currently recommended anti-influenza medications. It highlights the promising new drug baloxavir marboxil, and suggests further research on combination therapy.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Immunology
Chia-Ping Su, K. Arnold Chan, Ching-Tai Huang, Chi-Tai Fang
Summary: The study shows that inhaled zanamivir is as effective as oral oseltamivir in preventing influenza-related hospitalization or death for outpatients.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Yu-Hsing Fang, Tzu-Herng Hsu, Tzu-Yin Lin, Chia-Hung Liu, Shou-Chu Chou, Jie-Ying Wu, Pang-Chung Perng
Summary: The study compared the efficacy of IV peramivir and oral oseltamivir treatments in influenza patients, showing similar clinical efficacy between the two treatments with no significant difference.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2021)
Article
Chemistry, Medicinal
Xun Lv, Pengfei Wang, Chenning Li, Shuihong Cheng, Yuhai Bi, Xuebing Li
Summary: The conjugation of cholesterol to ZNV shows improved antiviral efficacy and can effectively protect mice from influenza virus infection. This new treatment has the potential for sustained therapeutic effects and provides an effective strategy for improving the pharmacokinetics and efficacy of other small-molecule therapeutics.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Infectious Diseases
Yu-Hsiang Hsieh, Andrea F. Dugas, Frank LoVecchio, Breana McBryde, Erin P. Ricketts, Kathryn Saliba-Shaw, Richard E. Rothman
Summary: The study compared outcomes of high-risk emergency department patients treated with IV peramivir versus oral oseltamivir, and found that both treatment options were similarly effective in managing influenza infections.
INFLUENZA AND OTHER RESPIRATORY VIRUSES
(2021)
Article
Pharmacology & Pharmacy
Andrei A. Ivashchenko, Jeremy C. Jones, Dmitry O. Shkil, Yan A. Ivanenkov, Philippe Noriel Q. Pascua, Melissa K. Penaflor, Ruben N. Karapetian, Elena A. Govorkova, Alexandre V. Ivachtchenko
Summary: In this study, the efficacy of a new orally-dosed neuraminidase inhibitor (NAI) AV5080 against different subtypes of influenza viruses was examined. AV5080 showed superior in vitro efficacy compared to currently approved NAIs, oseltamivir and zanamivir. However, it exhibited reduced inhibition against certain viral variants, such as NA-E119G and NA-R292K. These findings suggest that AV5080 is a promising orally-dosed NAI.
ANTIVIRAL RESEARCH
(2023)
Article
Infectious Diseases
Maki Kiso, Seiya Yamayoshi, Yoshihiro Kawaoka
Summary: This study discovered mutations in influenza viruses that confer resistance to neuraminidase inhibitors and baloxavir, and evaluated the effectiveness of oseltamivir, baloxavir, and favipiravir against these mutant viruses. The results showed that favipiravir was effective in treating infections caused by these mutant viruses, while oseltamivir and baloxavir were not.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Ming Xu, Ting Cai, Tingting Yue, Pan Zhang, Jie Huang, Qi Liu, Yue Wang, Ruping Luo, Zhengqiu Li, Linli Luo, Chunyi Ji, Xinrui Tan, Yanling Zheng, Richard Whitley, Erik De Clercq, Qiang Yin, Guangdi Li
Summary: This study evaluated the effectiveness of oseltamivir versus peramivir in young children (aged 0-5 years) infected with severe influenza A or influenza B. It found that oseltamivir demonstrated improved recovery and shorter hospitalization in the treatment of severe influenza A in hospitalized children.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Multidisciplinary Sciences
Najat Bdeir, Prerna Arora, Sabine Gaertner, Stefan Poehlmann, Michael Winkler
Summary: The presence of multiple DI RNAs derived from genomic segments encoding polymerase subunits might not result in increased antiviral activity, showing no significant impact on viral replication and interferon induction.
SCIENTIFIC REPORTS
(2021)
Article
Virology
Mengwei Li, Yuxu Wang, Jing Jin, Jie Dou, Qinglong Guo, Xue Ke, Changlin Zhou, Min Guo
Summary: The study reveals that honeysuckle acids and flavonoids extracts are the major antiviral active components, showing inhibitory effects against influenza viruses. Honeysuckle extracts have a broad-spectrum inhibitory effect on the neuraminidase of influenza viruses.
Article
Immunology
Hong-Dou Chen, Xu Wang, Shu-Le Yu, Yue-Hui Ding, Meng-Lei Wang, Jin-Na Wang
Summary: This study evaluated the efficacy of peramivir and oseltamivir in the treatment of severe influenza A with primary viral pneumonia, showing that peramivir is no less effective than oseltamivir. Patients treated with peramivir had significantly shorter remission times of fever symptoms than those treated with oseltamivir, providing guidance for clinical medication.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Hitoshi Yonezawa, Shingo Tanaka, Makito Tanaka, Ryo Kobayashi, Satoshi Takahashi
Summary: The aim of this study was to identify the risk factors for false positives in high-sensitivity HBsAg quantitative tests and reduce the need for neutralization tests. The results showed that younger age, female sex, lower HBsAg values, and reagent improvement were independent risk factors for false positives. The false-positive rate was highest in the range of 0.005-0.049 IU/mL.
JOURNAL OF INFECTION AND CHEMOTHERAPY
(2024)
Article
Infectious Diseases
Nobuaki Kobayashi, Katsushi Tanaka, Suguru Muraoka, Kohei Somekawa, Ayami Kaneko, Sousuke Kubo, Hiromi Matsumoto, Hiroaki Fujii, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko
Summary: This study identified age, a negative T-SPOT.TB result, elevated CRP levels, and a high NLR as significant independent risk factors for death in hospitalized TB patients. These findings underscore the importance of these parameters in the risk stratification and management of hospitalized TB patients.
JOURNAL OF INFECTION AND CHEMOTHERAPY
(2024)
Article
Infectious Diseases
Naokuni Hishiya, Kenji Uno, Akiyo Nakano, Mitsuru Konishi, Seiya Higashi, Shuhei Eguchi, Tadashi Ariyoshi, Asami Matsumoto, Kentaro Oka, Motomichi Takahashi, Yuki Suzuki, Saori Horiuchi, Nobuyasu Hirai, Yoshihiko Ogawa, Taku Ogawa, Ryuichi Nakano, Keiichi Mikasa, Kei Kasahara, Hisakazu Yano
Summary: This study revealed intestinal dysbiosis near a CD4 count of 350 in HIV-infected patients undergoing cART. These findings contribute to the understanding of intestinal damage and systemic inflammation in HIV infection.
JOURNAL OF INFECTION AND CHEMOTHERAPY
(2024)